CareDx, Inc. is dedicated to improving the lives of organ transplant patients through noninvasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx strives to stay at the forefront of organ transplant surveillance solutions. About AlloMap® AlloMap Molecular Expression Testing is a non-invasive blood test used to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment. AlloMap testing measures the expression levels of 20 genes from a blood sample. The combined expression of these genes is represented as an AlloMap test score. AlloMap is performed in the CareDx CLIA-certified laboratory and has been commercially available in the United States since 2005. AlloMap was cleared by the U.S. Food and Drug Administration in 2008 and was CE marked for the European Union in 2011. Use of AlloMap is also included in the International Society for Heart and Lung Transplantation (ISHLT) Practice Guidelines, published in August 2010, the worldwide standard for the care of heart transplant patients.
Company Growth (employees)
Type
Public
HQ
Brisbane, US
Size (employees)
55 (est)
CareDx is headquartered in Brisbane, US

CareDx Office Locations

CareDx has an office in Brisbane
Brisbane, US (HQ)
3260 Bayshore Blvd

CareDx Data and Metrics

CareDx Financial Metrics

CareDx's revenue was reported to be $40.6 m in FY, 2016 which is a 44% increase from the previous period.
Numbers are in $, USD

Revenue (FY, 2016)

40.6 m

Revenue growth (FY, 2015 - FY, 2016), %

44%

Net income (FY, 2016)

(39.8 m)

EBIT (FY, 2016)

(37.3 m)

Market capitalization (22-Jun-2017)

23.6 m

Closing share price (22-Jun-2017)

1.1

Cash (31-Dec-2016)

17.3 m

EV

30.2 m
CareDx's current market capitalization is $23.6 m.
FY, 2014FY, 2015FY, 2016

Revenue

27.3 m28.1 m40.6 m

Revenue growth, %

3%44%

Sales and marketing expense

6.5 m8.3 m11.2 m

R&D expense

3.8 m9.3 m12.4 m

General and administrative expense

8.4 m12.2 m20.7 m

Operating expense total

26.1 m40.1 m78 m

EBIT

1.3 m(11.9 m)(37.3 m)

EBIT margin, %

5%(42%)(92%)

Interest expense

(2.1 m)(1.6 m)(1.9 m)

Pre tax profit

(719 k)(13.7 m)(41.4 m)

Income tax expense

1.5 m1.6 m

Net Income

781 k(13.7 m)(39.8 m)
FY, 2014FY, 2015FY, 2016

Cash

36.4 m29.9 m17.3 m

Accounts Receivable

2.7 m2.4 m2.8 m

Inventories

686 k766 k5.5 m

Current Assets

40.3 m34.4 m26.7 m

PP&E

2 m2.4 m2.9 m

Goodwill

12 m12 m13.8 m

Total Assets

61.1 m55.6 m76.7 m

Accounts Payable

1.1 m1.6 m3.1 m

Total Debt

15.8 m23.9 m

Current Liabilities

11.1 m10.2 m40.8 m

Additional Paid-in Capital

200.7 m202.6 m235.7 m

Retained Earnings

(159.4 m)(173.1 m)(212.6 m)

Total Equity

41.3 m29.5 m19.8 m

Debt to Equity Ratio

0.5 x1.2 x

Debt to Assets Ratio

0.3 x0.3 x

Financial Leverage

1.5 x1.9 x3.9 x
FY, 2014FY, 2015FY, 2016

Net Income

781 k(13.7 m)(39.8 m)

Depreciation and Amortization

512 k796 k2.9 m

Accounts Receivable

(417 k)320 k1 m

Inventories

(168 k)(80 k)492 k

Accounts Payable

510 k489 k(620 k)

Cash From Operating Activities

31.3 m(9.8 m)(16.5 m)

Purchases of PP&E

(733 k)(1.2 m)(549 k)

Cash From Investing Activities

(1.3 m)(1.2 m)(21.1 m)

Cash From Financing Activities

36 m4.4 m24.9 m

Interest Paid

1.2 m1.4 m867 k
Y, 2016

EV/EBIT

-0.8 x

EV/CFO

-1.8 x

Debt/Equity

1.2 x

Debt/Assets

0.3 x

Financial Leverage

3.9 x

CareDx Market Value History

CareDx Online and Social Media Presence

CareDx Company Life and Culture

You may also be interested in